GlassScriptPhysician profile
David Frank Dies
NPI 1205826419
$100,101.13
in general payments reported to CMS, 2019-2025
23 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $16K · 2021: $4,704 · 2022: $1,033 · 2023: $867 · 2024: $564 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,593.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $67,954.65 | 2019-2025 | Rinvoq, Skyrizi |
| Gilead Sciences, INC. | $30,453.73 | 2019-2025 | Epclusa, Vemlidy |
| Boston Scientific Corporation | $342.70 | 2022-2025 | General - Hemostasis, Exalt Model D |
| Takeda Pharmaceuticals U.S.A., INC. | $192.58 | 2019-2025 | Entyvio |
| Celgene Corporation | $143.20 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $138.59 | 2025 | Rezdiffra |
| Perspectum Diagnostics LTD | $123.35 | 2023 | Livermultiscan |
| Mirum Pharmaceuticals, INC. | $122.14 | 2025 | Livmarli |
| Ucb, INC. | $121.94 | 2019 | |
| Genzyme Corporation | $91.54 | 2022-2025 | |
| Celltrion USA INC. | $80.23 | 2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.94 | 2021-2023 | Xifaxan |
| Erbe USA INC | $50.00 | 2024 | |
| Daiichi Sankyo INC. | $49.57 | 2019-2022 | |
| Qol Medical, LLC | $38.06 | 2023-2024 | Sucraid, Sucraid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $29.63 | 2022-2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $28.93 | 2019-2023 | Ocaliva |
| Novo Nordisk INC | $21.97 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $19.77 | 2023 | Dupixent |
| Janssen Biotech, INC. | $19.08 | 2019 | |
| Covidien LP | $17.53 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.